A randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Safety and efficacy results.

被引：0

作者：

Van Cutsem, E.

Eng, C.

Tabernero, J.

Nowara, E.

Swieboda-Sadlej, A.

Tebbutt, N. C.

Mitchell, E. P.

Davidenko, I.

Chen, L.

Smethurst, D.

机构：

[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Maria Sklodowska Curie Mem Canc Ctr, Dept Clin & Expt Oncol, Gliwice, Poland

[5] Inst Oncol, Gliwice, Poland

[6] Warszawski Uniwersytet Med, Warsaw, Poland

[7] Austin Hlth, Heidelberg, Vic, Australia

[8] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[9] Krasnodar City Oncol Ctr, Krasnodar, Russia

[10] Amgen Inc, Thousand Oaks, CA USA

[11] Amgen Inc, Uxbridge, Middx, England

来源：

关键词：

D O I：

10.1200/jco.2011.29.4_suppl.366

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

366

引用

页数：1